SPECTRUM PHARMACEUTICALS INC

Form SC 13G/A September 19, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 1

Spectrum Pharmaceuticals
(Name of Issuer)

Common Stock (Title of Class of Securities)

84763A108 (CUSIP Number)

September 12, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [x] Rule 13d-1(b)
- [] Rule 13d-1(c)
- [] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 84763A108

- Names of Reporting Persons.
 I.R.S. Identification Nos. of above persons (entities only).
 - OrbiMed Advisors LLC
- 2. Check the Appropriate Box if a Member Of a Group (See Instructions)
 - [] (a)
 - [] (b)

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power: 0

Number of

Shares 6. Shared Voting Power: 777,795

Beneficially

Owned by 7. Sole Dispositive Power: 0

Each Reporting

Person With 8. Shared Dispositive Power: 777,795

- Aggregate Amount Beneficially Owned by Each Reporting Person 777,795
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 3.06%
- 12. Type of Reporting Person (See Instructions) IA

CUSIP No. 84763A108

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Capital LLC

- 2. Check the Appropriate Box if a Member of a Group (See Instructions)
 - [] (a)
 - [] (b)
- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power: 0

Number of

Shares 6. Shared Voting Power: 458,193

Beneficially

Owned by 7. Sole Dispositive Power: 0

Each Reporting

Person With 8. Shared Dispositive Power: 458,193

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 458,193
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

- 11. Percent of Class Represented by Amount in Row (9) 1.80%
- 12. Type of Reporting Person (See Instructions) IA

CUSIP No. 84763A108

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).

Samuel D. Isaly

- 2. Check the Appropriate Box if a Member of a Group (See Instructions)
 - [] (a)
 - [] (b)
- 3. SEC Use Only
- 4. Citizenship or Place of Organization

United States

5. Sole Voting Power: 0

Number of

Shares 6. Shared Voting Power: 1,235,988

Beneficially

Owned by 7. Sole Dispositive Power: 0

Each Reporting

Person With 8. Shared Dispositive Power: 1,235,988

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,235,988
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 4.86%**
- 12. Type of Reporting Person (See Instructions) HC
- Item 1. (a) Issuer: Spectrum Pharmaceuticals
 - 1. Address: 157 TECHNOLOGY DR IRVINE CA 92618
- Item 2. (a) Name of Person Filing:
 OrbiMed Advisors LLC
 OrbiMed Capital LLC
 Samuel D. Isaly
 - (b) Address of Principal Business Offices:

767 Third Avenue, 30th Floor New York, New York 10017

- (c) Citizenship:
 Please refer to Item 4 on each cover sheet for each filing person
- (d) Title of Class of Securities
 Common stock
- (e) CUSIP Number: 84763A108

Item 3. OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1 (b) (1) (ii) (E). Samuel D. Isaly is a control person in accordance with ss.240.13d-1 (b) (1) (ii) (G).

Item 4. Ownership

Please see Items 5 - 9 and 11 for each cover sheet for each filing separately

Item 5. Ownership of Five Percent or Less of a Class

Reporting persons are holding 4.86% of the securities on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, such securities. No one such other person's interest in the securities whose ownership is reported here relates to more than five percent of the class.

OrbiMed Advisors LLC and OrbiMed Capital LLC hold shares on behalf of Caduceus Capital Master Fund Limited (87,662 shares and 294,531 warrants), Caduceus Capital II, L.P. (45,500 shares and 153,000 warrants), UBS Eucalyptus Fund, LLC (74,300 shares and 250,000 warrants), PW Eucalyptus Fund, Ltd. (7,500 shares and 25,000 warrants), HFR SHC Aggressive Fund (17,500 shares and 58,500 warrants), Knightsbridge Post Venture IV L.P. (10,545 shares and 35,500 warrants), Knightsbridge Integrated Holdings, V, LP (11,700 shares and 39,500 warrants), Knightsbridge Netherlands II, LP (3,000 shares and 10,000 warrants), Knightsbridge Integrated Holdings IV Post Venture, LP (4,500 shares and 15,000 warrants), Knightsbridge Post Venture III, LP (3,000 shares and 9,750 warrants), Knightsbridge Netherlands I LP (2,800 shares and 9,400 warrants), Knightsbridge Netherlands III LP (2,900 shares and 9,650 warrants), Knightsbridge Integrated Holdings II Limited (3,600 shares and 12,250 warrants), Knightsbridge Venture Completion 2005 LP (1,100 shares and 3,750 warrants), and Knightsbridge Venture Capital VI LP (3,000 shares and 10,150 warrants), Knightsbridge Venture Capital IV LP (2,900 shares and 9,600 warrants), and Knightsbridge Venture Capital III LP (2,100 shares and 6,800 warrants).

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Not Applicable

Item 8. Identification and Classification of Members of the Group

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 19, 2006

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

Title: President

OrbiMed Capital LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

By: /s/ Samuel D. Isaly
----Name: Samuel D. Isaly

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G/A, dated September 19,2006, (the "Schedule 13G/A"), with respect to the Common Stock, par value \$.001 per share, of Spectrum Pharmaceuticals is filed on behalf of

each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 19th day of Sepember, 2006.

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

OrbiMed Capital LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

Title: Managing Member

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

Statement of Control Person

The Statement on this Schedule 13G/A dated September 19, 2006 with respect to the common stock, \$.001 par value per share, of Spectrum Pharmaceuticals is filed by Samuel D. Isaly in accordance with the provisions of Rule 13d-1 (b) and Rule 13d-1 (k), respectively, as control person (HC) of OrbiMed Advisors LLC and OrbiMed Capital LLC.

OrbiMed Advisors LLC and OrbiMed Capital LLC file this statement on Schedule 13G/A in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as investment advisors (IA).